PP.01.02

Abstract

Objective: To study the daily dynamic profile of blood pressure among patients with hypertension and acute coronary syndrome (ACS) associated with anxiety and depressive disorders. Design and method: 46 patients with AH and ACS and with anxiety and depressive symptoms were included in open comparative prospective research. Were examined using Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI) and The Sheehan Scale (Sheehan Clinical Anxiety Rating Scale). The first group patients were treated by conventional therapy and received additional Agomelatine (Valdoxane, SERVIER), 25 mg/day. Patients in the second group were given placebo. After 6 months we recorded the dynamics of clinical status, mental status and quality of life on the hospital stage, ABPM. Results: The HADS survey showed clinically marked anxiety and subclinically marked depression. The Beck survey showed the level of depression in averaged 25,8 ± 7 points in the Valdoxane group, 22,2 ± 6,66 points - in the placebo group, which was an average degree of depression. The Sheehan scale was used to see the level of anxiety. At first survey patients in both groups had clinically marked anxiety (from 30 to 80 points). Both groups were put a daily monitoring of blood pressure. This showed SBP and DBP increase and increased BP variability in both groups. After 6 months in the placebo group statistically significant changes in mental status had not been identified. And in the Valdoxane group significant positive changes in evaluation of the anxiety and depression level were revealed in all scales. After 6 months of the treatment a progress of the target level of SBP, DBP was revealed in both treatment groups. BP variability in the Valdoxane group amounted to the target level. In the placebo group - remained elevated. Conclusions: To supplement Valdoxane in standard therapy of hypertension and ACS facilitates in reducing of BP in contrast with placebo group. Where reduce BP variability failed, in spite of achieving targets blood pressure.